孟詳喻簡(jiǎn)介
姓 名： 孟詳喻
性 別：男
最高學(xué)位：博士
職 稱：副教授
職 務(wù)：無(wú)
mail ： [email protected]
電 話：15827268359
研究方向：干濕結(jié)合的疾病機(jī)制與轉(zhuǎn)化研究
個(gè)人簡(jiǎn)介：
孟詳喻，1990年生，湖北恩施人，土家族，博士，副教授，碩士研究生導(dǎo)師。本碩連讀畢業(yè)于武漢大學(xué)（臨床醫(yī)學(xué)七年制中法班），期間先后赴法國(guó)洛林大學(xué)（法國(guó)政府獎(jiǎng)學(xué)金資助）和日本北海道大學(xué)訪問(wèn)學(xué)習(xí)。博士畢業(yè)于巴黎薩克雷大學(xué)（ARWU排名全球12，THE排名全球64），師從膀胱癌領(lǐng)軍學(xué)者F. Radvanyi教授，從事膀胱癌腫瘤生物學(xué)研究。
中國(guó)農(nóng)工民主黨黨員。
省級(jí)人才計(jì)劃入選者。
任湖北省生物信息學(xué)會(huì)理事、歐洲腫瘤內(nèi)科學(xué)會(huì)ESMO會(huì)員、全法中國(guó)科技工作者協(xié)會(huì)會(huì)員、亞太生物醫(yī)學(xué)免疫學(xué)會(huì)血液學(xué)專委會(huì)委員、湖北省醫(yī)學(xué)生物免疫學(xué)會(huì)血液學(xué)專委會(huì)與青年委員會(huì)委員。《臨床內(nèi)科雜志》通訊編委、Phenomics青年編委、iMeta青年編委、Oncology and Translational Medicine青年編委。Advanced Science、British Journal of Psychiatry、 Haematologica、HemaSphere、Journal of Advanced Research、Biomarker Research、MedComm、Clinical and Translational Medicine、Briefings in Bioinformatics、Scientific Data、Journal of Agricultural and Food Chemistry等數(shù)十本SCI期刊審稿人。
以第一/共一/通訊作者在European Urology (IF: 25.3，中科院1區(qū)top；3篇，含1篇封面論文)、Genome Medicine (IF: 10.4，中科院1區(qū)top)、Molecular Cancer (IF: 27.7，中科院1區(qū)top)、Advanced Science (IF: 14.3，中科院1區(qū)top)、Journal of Hematology & Oncology (IF: 29.5，中科院1區(qū)top) 、Theranostics (IF: 12.4，中科院1區(qū)top)、Clinical Chemistry (IF: 7.1，ADLM會(huì)刊，醫(yī)學(xué)檢驗(yàn)技術(shù)第一刊，中科院小類1區(qū))、Journal for ImmunoTherapy of Cancer (IF: 10.3，中科院1區(qū)top) 、Advanced Healthcare Materials (IF: 10.0) 、Clinical and Translational Medicine (IF: 7.9)等高影響力期刊發(fā)表論文多篇，總引用>1,700，H-index 25。
(Google Scholar，https://scholar.google.com/citations?hl=en&user=JQYDHSkAAAAJ&view_op=list_works&sortby=pubdate)
通曉英（TOEFL iBT, CEFR C1）、法（TEF, CECR B2）、日（JLPT, N1）三門外語(yǔ)。
主持、參與的項(xiàng)目：
1. 湖北省高層次人才項(xiàng)目，楚天英才計(jì)劃“楚天學(xué)者”，主持；
2. 法國(guó)國(guó)家健康與醫(yī)學(xué)研究院（INSERM）ITMO Cancer AVIESAN Soutien pour la formation à la recherche fondamentale et translationnelle en Cancérologie博士基金項(xiàng)目，21.5萬(wàn)歐元，主持；
3. 國(guó)家自然科學(xué)基金青年項(xiàng)目，APOBEC3A驅(qū)動(dòng)膀胱癌發(fā)生發(fā)展的動(dòng)物模型及其機(jī)制研究，30萬(wàn)元，主持；
4. 國(guó)家自然科學(xué)基金面上項(xiàng)目，FGFR3突變介導(dǎo)受體過(guò)度激活和免疫抑制誘導(dǎo)膀胱癌發(fā)生和治療耐藥的分子機(jī)制，49萬(wàn)元，參與（2/7）；
5. 湖北省自然科學(xué)基金青年項(xiàng)目，APOBEC3A驅(qū)動(dòng)膀胱癌發(fā)生和惡性進(jìn)展的體內(nèi)機(jī)制研究，5萬(wàn)元，主持；
6. 教育部學(xué)位與研究生教育發(fā)展中心主題案例項(xiàng)目，利用多組學(xué)技術(shù)研究土家醫(yī)道地藥材治療阿爾茲海默病的有效成分及其作用機(jī)制研究案例，參與（3/6）；
7. 湖北民族大學(xué)博士科研啟動(dòng)基金及省級(jí)重點(diǎn)實(shí)驗(yàn)平臺(tái)開(kāi)放課題等多項(xiàng)，主持。
科研教學(xué)成果及獎(jiǎng)勵(lì)：
1. “基于尿液cfDNA的膀胱癌早篩液體活檢關(guān)鍵技術(shù)及試劑盒研發(fā)”，第五屆全國(guó)設(shè)備管理與技術(shù)創(chuàng)新成果二等獎(jiǎng)，2022，中國(guó)設(shè)備管理協(xié)會(huì).
2. “優(yōu)福能—膀胱癌早篩尖端方案”，2021年中國(guó)國(guó)際“互聯(lián)網(wǎng)+”大學(xué)生創(chuàng)新創(chuàng)業(yè)大賽國(guó)家級(jí)銅獎(jiǎng)，2021，中國(guó)國(guó)際“互聯(lián)網(wǎng)+”大學(xué)生創(chuàng)新創(chuàng)業(yè)大賽組織委員會(huì).
公開(kāi)發(fā)表論文、教材、專著及課程建設(shè)：
論文（*，通訊；#，第一/共一）：
Xiang-Yu Meng#. Cyclic enrichment of urinary exosomes using a MOF-on-MOF-based asymmetric impinging streams chip for bladder cancer diagnosis and prognosis prediction. Adv Healthc Mater. 2025, in press. (IF: 10.0，中科院2區(qū)).
Xiang-Yu Meng#,*. Gene and pathway analysis of genome-wide genetic associations of bladder cancer. Curr Urol. 2025, in press. (IF: 0.9，中科院4區(qū)).
Xiang-Yu Meng*. SysNatMed: rational natural medicine discovery by systems genetics. Front Pharmacol. 2025:1496061 (IF: 4.4, 中科院3區(qū)).
Xiang-Yu Meng*. Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications. Mol Cancer. 2024:265 (IF: 27.7, 中科院1區(qū)top)
Xiang-Yu Meng#. Machine learning-based detection of bladder cancer by urine cfDNA fragmentation hotspots that capture cancer-associated molecular features. Clin Chem. 2024, 70(12):1463-1473 (IF: 7.1, ADLM official journal, 中科院小類1區(qū)).
Xiang-Yu Meng*. Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns. Adv Sci (Weinh). 2024:e2308243 (IF: 14.3, 中科院1區(qū) top).
Xiang-Yu Meng#,*. Sex bias in FGFR3 somatic mutations in bladder cancer. Oncol Trans Med. 2024, 10(5): 252-256 (CSTPCD).
Xiang-Yu Meng*. Single-cell analyses reveal evolution mimicry during the specification of breast cancer subtype. Theranostics. 2024, 14(8):3104-3126 (IF: 12.4, 中科院1 區(qū)top).
Xiang-Yu Meng*. The underexplored role of APOBEC3 enzymes in autoimmune diseases. Rheumatology (Oxford). 2024, 63(6):e166-e167 (IF: 4.7, 中科院2區(qū)).
Xiang-Yu Meng*. Landscape of urine biomarkers for bladder cancer: molecular function, cell-of-origin, and bibliometric trend. Oncol Trans Med. 2024, 10(3):132-142 (CSTPCD).
Xiang-Yu Meng#,*. Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed. Epigenomics. 2023, 15(22):1175-1178 (IF: 3.0, 中科院4區(qū)).
Xiang-Yu Meng#,*. Historical pathogen-driven selection may contribute to contemporary ethnic difference in bladder cancer susceptibility. Bladder Cancer. 2023, 9(3): 211-216 (IF: 1.0, 中科院4區(qū); BCAN official journal)
Xiang-Yu Meng#,*. Comments on “Methylation scores for smoking, alcohol consumption and body mass index and risk of seven types of cancer”. Int J Cancer. 2023, 153(8):1543-1544 (IF: 5.7, 中科院2區(qū)).
Xiang-Yu Meng#,*. NLRC5 germline variants as potential pharmacogenomic markers for immune checkpoint inhibitors. J Immunother Cancer. 2023, 11(6):e007255 (IF: 10.3, 中科院1區(qū) top).
Xiang-Yu Meng*. The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer. J Transl Med. 2023, 21(1):298 (IF: 6.1, 中科院2 區(qū)top).
Xiang-Yu Meng#,*. “Paradoxical neoantigenic mutations”: not simply a driver vs passenger dualism. Br J Cancer. 2023, 129(1):1-2 (IF: 6.4, 中科院2 區(qū)top).
Xiang-Yu Meng#. FGFR3 mutational activation can induce luminal-like papillary bladder tumor formation and favors a male sex bias. Eur Urol. 2023, 83(1):70-81 (IF: 25.3, 中科院1 區(qū)top).
Xiang-Yu Meng*. Dynamic gene screening enabled identification of a 10-gene panel for early detection and progression assessment of gastric cancer. Comput Struct Biotechnol J. 2022, 21:677-687. (IF: 4.4, 中科院3區(qū))
Xiang-Yu Meng*. Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer. J Hematol Oncol. 2022, 15(1):19 (IF: 29.5, 中科院1區(qū) top).
Xiang-Yu Meng#,*. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. Genome Med. 2020, 12(1):85 (IF: 10.4, 中科院1區(qū) top; Feature).
Xiang-Yu Meng*. ΔNp63 drives epithelial differentiation in glioma. Clin Transl Med. 2020, 10(4):e165 (IF: 7.9, 中科院2區(qū) top).
Xiang-Yu Meng#. Estimation and projection about the standardized prevalence of osteoporosis in mainland China. Calcif Tissue Int. 2020, 106(2):131-146 (IF: 3.3, 中科院3區(qū)).
Xiang-Yu Meng#. Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019, 76:9-13. Eur Urol. 2020, 77(1):e24-e25 (IF: 25.3, 中科院1區(qū) top).
Xiang-Yu Meng#. APOBEC-mediated mutagenesis as a likely cause of FGFR3 S249C mutation over-representation in bladder cancer. Eur Urol. 2019, 76(1):9-13 (IF: 25.3, 中科院1區(qū) top; Cover).
Xiang-Yu Meng#. The role of COL5A2 in patients with muscle-invasive bladder cancer: a bioinformatics analysis of public datasets involving 787 subjects and 29 cell lines. Front Oncol. 2019, 8:659 (IF: 3.5, 中科院3區(qū)).
Xiang-Yu Meng*. Long-term efficacy of maintenance therapy for multiple myeloma: A quantitative synthesis of 22 randomized controlled trials. Front Pharmacol. 2018, 9:430 (IF: 4.4, 中科院3區(qū)).
Xiang-Yu Meng*. Bortezomib, thalidomide, and dexamethasone (VTD) induction results in better overall survival than adriamycin, thalidomide, and dexamethasone (ATD) induction in previously untreated myeloma patients eligible for transplants. Acta Haematol. 2017, 137(4):207-208 (IF: 1.7, 中科院4區(qū)).
Xiang-Yu Meng*. La relation entre la récurrence de la tumeur et les polymorphismes génétiques de hGPX1 et NRAMP1 chez les patients atteints du cancer superficiel de la vessie: une méta-analyse. Pan Afr Med J. 2017, 27: 270 (in French).
Xiang-Yu Meng*. Baicalein suppresses the proliferation of acute T-lymphoblastic leukemia Jurkat cells by inhibiting the Wnt/β-catenin signaling. Ann Hematol. 2016, 95(11):1787-93 (IF: 3, 中科院3區(qū)).
教材及專著：
《DK人體百科（涂色版）》，2019，北京科學(xué)技術(shù)出版社，主譯
《人體筋膜系統(tǒng)功能學(xué)圖譜》，2017，北京科學(xué)技術(shù)出版社，副主譯
《應(yīng)用STATA做Meta分析》，2016，中國(guó)協(xié)和醫(yī)科大學(xué)出版社，編者
《循證臨床實(shí)踐指南的研發(fā)與評(píng)價(jià)》，2016，中國(guó)協(xié)和醫(yī)科大學(xué)出版社，編者
《R與Meta分析》，2016，軍事醫(yī)學(xué)科學(xué)出版社，編者